Purpose {#S0001}
=======

Aside from non-melanoma skin cancer, prostate cancer (PC) is the most common cancer in men in the United States and Europe, with a rapid increasing incidence in the last two decades \[[@CIT0001]\]. Radiotherapy is one of the most important curative options in treating localized PC. For high-risk PC, standard dose (70 Gy) plus long-term anti-androgen therapy became the gold standard after the publication of EORTC 22863 \[[@CIT0002]\] and RTOG 92-02 \[[@CIT0003]\] trial results. Furthermore, Pollack *et al*. \[[@CIT0004]\] shown that dose escalation (78 Gy) was a key point for biochemical control. Many studies have confirmed positive effect of dose escalation on disease local control using radiation therapy \[[@CIT0005]--[@CIT0008]\]. However, dose escalation delivered through 3D external beam radiation therapy (EBRT) was associated with a higher rate of gastro-intestinal (GI) and genito-urinary (GU) toxicities \[[@CIT0009]\]. Using intensity modulated radiation therapy (IMRT), Zelefsky *et al*. \[[@CIT0010]\] shown that a total dose of 81 Gy could be delivered to the prostate increasing the rate of biochemical control without increasing the rate of GU and GI toxicities. Intensity-modulated radiation therapy for PC is generally performed through 8 to 9 consecutive weeks; nevertheless, due to the low α/β ratio of the prostatic tissue, clinical research was directed toward hypofractionation concept. Randomized trials comparing standard radiation dose (2 Gy/f, 1.8 Gy/f) versus "soft" hypofractionated regimen (2.5 Gy/f to 3 Gy/f) using EBRT confirmed that the two regimens were equivalent in terms of acute and late toxicity \[[@CIT0011], [@CIT0012]\]. High-dose rate (HDR) brachytherapy boost following EBRT delivering a total dose of 46 Gy to the pelvis or prostatic fossa, represents a smart technique to not only increase the dose to the prostate, but also significantly reduce the number of round trips to the radiation facility.

In February 2009, we integrated the HDR brachytherapy boost program in PC treatment. We used 3 different fractionation schemes consecutively. We report the results in terms of acute GU and GI toxicity observed between these three different regimens.

Material and methods {#S0002}
====================

Patient characteristics {#S20003}
-----------------------

Between February 2009 and July 2013, 216 consecutive patients underwent a HDR brachytherapy boost for PC. Over the study period, two different treatment planning systems (TPS) were used: Plato™ (Nucletron BV, Veenendaal, The Netherlands) from February 2009 to May 2012, and Oncentra Brachy™ (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) from June 2012 until now. In order to avoid any comparative bias, we analysed the first 124 patients treated with the same TPS (Plato™). From 02/2009 to 01/2010, 30 patients (Group 1 = G1; 24%) were treated with 3 × 6 Gy over 2 days. In order to make this procedure more comfortable for the patient and less time-consuming for the medical staff, from 01/2010 to 01/2011, 52 patients (Group 2 = G2; 42%) received 2 fractions of 9 Gy over 2 days, while from 01/2011 to 05/2012, 42 patients (Group 3 = G3; 34%) were treated with a single fraction of 14 Gy. This observational study retrospectively analysed the acute GU and GI toxicities occurred during the first 6 months after the implant in the 3 treatment groups. The 3 different fractionation regimens were approved by the institutional review board.

All the patients presented with a histologically proved non-metastatic PC. All the patients underwent imaging studies, including magnetic resonance, computed tomography, and bone scan. Appropriate patient selection was performed according to the American Brachytherapy Society (ABS) consensus guidelines for HDR prostate brachytherapy \[[@CIT0013]\].

Irradiation treatment techniques and planning {#S20004}
---------------------------------------------

Patients were treated with a first course of EBRT, delivering 46 Gy in 23 fractions. 3D conformal EBRT was used for achieving this first treatment step. The dose was delivered to the ICRU point using high-energy X-photons (\> 10 MV). According to the calculated risk of lymph node involvement, the clinical target volume (CTV) was the whole pelvis or the prostatic fossa (prostate and seminal vesicles) for high- (≥ 15%) and low-risk (\< 15%) of lymph node involvement, respectively \[[@CIT0014]\]. The planning target volume (PTV) was defined as a 1 cm margin around the CTV in all directions, and reduced to 5 mm at the prostate rectal interface. Short and long-term androgen deprivation therapy (ADT) was proposed to intermediate and high-risk patients, respectively.

After completion of the EBRT, patients underwent HDR brachytherapy boost. This procedure was performed under general anaesthesia. Using TransRectal UltraSound (TRUS) guidance, 15 to 17 catheters (Sharp Needles™; Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) were implanted transperineally and periurethrally through a dedicated template. After recovery, post-implant planning CT-scan was directly performed in the radiation oncology department for treatment planning purposes. CTV (prostate) and organs at risk (OAR -- urethra and rectum) were outlined \[[@CIT0015]\]. The prostatic portion of the urethra was outlined plus a 10 mm additional margin above the base and below the apex, while the rectum was outlined from the anorectal junction to the rectosigmoid junction. Brachytherapy boost delivered 3 × 6 Gy, 2 × 9 Gy, and 1 × 14 Gy for G1, G2, and G3, respectively. Considering α/β 1.5 Gy for prostatic tissue, EQD2 (equivalent dose at 2 Gy/fraction) were 39 Gy, 54 Gy, and 62 Gy for G1, G2, and G3, respectively \[[@CIT0016]\]. Dose constraints for prostate were V~100~ (CTV receiving 100% of the prescribed dose) \> 95%, V~150~ \< 35%, and V~200~ \< 15%, D~90~ (dose delivered to 90% of CTV) \> 105%, and D~100~% \> 80%. Dose constraints used for OARs relied on the brachytherapy regimen groups. Because of the slight dose escalation between G1/G2 (EQD2~αβ1.5~ 39 Gy, 54 Gy) and G3 (EQD2~αβ1.5~ 62 Gy), more restrictive dose constraints were considered for G3 patients. Consequently, for G1/G2, Vu~125~ (percentage of the urethra volume receiving 125% of the prescribed dose) and Vr~100~ (percentage of the rectum volume receiving 100% of the prescribed dose) should be less than 1%, while for G3 patients, Vu~115~ (percentage of the urethra volume receiving 115% of the prescribed dose) and Vr~90~ (percentage of the rectum volume receiving 90% of the prescribed dose) should be less than 1% ([Fig. 1](#F0001){ref-type="fig"}). Dose-volume adaptation was manually achieved using graphical optimization (Platoä, Nucletron BV, Veenendaal, The Netherlands) by dwell location and time variation. Patients treated with multiple fractions after a single insertion were re-scanned before each fraction, followed by re-optimization with regard to the risk of catheter migration \[[@CIT0017]\]. The first fraction was given post-operatively (at day 0), while the following fractions were given at day 1 (with at least 6 hours interval between the 2^nd^ and 3^rd^ fraction for G1).

![Dose distribution obtained after planning using Plato (Nucletron BV, Veenendaal, The Netherlands) on sagittal (A) and transversal (B) view](JCB-5-21671-g001){#F0001}

Follow-up {#S20005}
---------

Patients were followed at 1 month after the implant, then every 6 months with an assessment of serum prostate specific antigen level (PSA), physical examination, patient symptom assessment, and digital rectal examination in case of rising PSA. Acute GU and GI toxicities were scored according to the Common Terminology Criteria for Adverse Event (CTCAE v3.0) \[[@CIT0018]\]. For GU complications, we analysed stricture/stenosis, frequency/urgency, retention, incontinence, cystitis and bladder spasms while for GI complications we analysed haemorrhoids, anal incontinence, and proctitis. Because a longer follow-up is needed to assess sexual toxicity, and due to the high number of patients who received ADT, this complication was not assessed. Follow-up evaluation was performed alternatively by radiation oncologist and urologist. Biochemical failure was defined as PSA nadir plus 2 ng/ml \[[@CIT0019]\].

Statistical analysis {#S20006}
--------------------

Data were entered and stored on an Access file, and then transferred into R.2.14.1 software for statistical analysis. Quantitative variables were summarized by means, standards deviation, medians, and range. Qualitative variables were described by counts and percentages. χ^2^ test or Fisher\'s exact test was used for category comparison. Student test or Wilcoxon\'s test was used to compare continuous variables. ANOVA or non-parametric Kruskal-Wallis was performed to test variables expressed as categories versus continuous variables. If this test was significant, we used the test of Tukey or Nemenyi test to compare these categories. We also showed the median survival and confidence intervals at 95% of the studied population (Kaplan-Meier method). Tests of significance were two-sided, and considered significant when the *p* value was 0.05 or less.

Results {#S0007}
=======

Patient and treatment characteristics {#S20008}
-------------------------------------

Patient and treatment characteristics are reported in [Table 1](#T0001){ref-type="table"}. Regarding patient (age, risk group factors) and treatment (EBRT, ADT) data, no significant differences were observed between the 3 treatment groups. Median age was 69.7 years (ranged 49-82). The majority of the patients were classified as high (73.4%) or intermediate (19.3%) risk regarding to D\'Amico classification \[[@CIT0020]\]. Sixty-five percent of the patients (81 patients) received whole pelvic EBRT while 80% (99 cases) underwent ADT. The median time interval between EBRT and HDR brachytherapy boost was 14 days (ranged 0-43).

###### 

Patient characteristics according to the treatment group

  Data                3 fractions (G1)   2 fractions (G2)   1 fraction (G3)   *p* value                   
  ------------------- ------------------ ------------------ ----------------- ------------ ---- --------- -------
  \# Pts              30                 24                 52                42           42   34        
  Age                 69                 (50-82)            70                (59-80)      68   (49-81)   0.250
  T stage                                                                                                 0.103
   T1c-2a-2b          12                 25                 15                31           21   44        
   T2c-3a-3b          18                 33                 37                49           21   28        
  PSAi                13                 (5.35-58)          21                (1.65-369)   13   (3-114)   0.6
  Gleason score                                                                                           0.4
   6                  9                  24                 15                39           14   37        
   7                  8                  17                 22                48           16   35        
   ≥ 8                13                 33                 15                37           12   30        
  Risk groups                                                                                             0.633
   Low                1                  12                 4                 50           4    38        
   Intermediate       5                  20                 8                 34           11   46        
   High               24                 27                 40                43           27   30        
  Pelvic EBRT                                                                                             0.149
   Yes                16                 20                 38                47           27   33        
   No                 14                 33                 14                33           15   34        
  ADT                                                                                                     0.110
   Yes                24                 24                 45                46           30   30        
   No                 6                  23                 7                 27           12   50        
  Int RT/Brachy (d)   12                 (0-43)             17                (1-42)       14   (5-32)    0.065

n -- number of patients, EBRT -- external beam radiation therapy, ADT -- androgen deprivation therapy, Int RT/Brachy -- time interval between the end of EBRT and high-dose rate brachytherapy expressed in days

Dosimetric data are reported in [Table 2](#T0002){ref-type="table"}. Because no significant dosimetric differences were noticed between G1/G2 patients regarding 1^st^, 2^nd^ and 3^rd^ post-implant CT-scan (data not shown), the 1^st^ CT-scan was used for dosimetric comparisons between the 3 treatment groups. Median CTV were equivalent in 3 groups (36, 33, and 32 cc for G1, G2, and G3, respectively, *p* = 0.088). D~90~ for G3 (105%) was significantly decreased compared to the D~90~ calculated for G1 (114%), and G2 (111%) (*p* \< 0.001) as well as V~100~ (97, 96, and 95% for G1, G2, and G3, respectively; *p* = 0.013), while V~150~ and V~200~ significantly decreased from G1 to G3 (V~150~: 45, 36, and 27% for G1, G2, and G3, respectively; *p* \< 0.001 and V~200~: 16, 12, and 9 for G1, G2, and G3, respectively *p* \< 0.001). Dose Homogeneity Index (DHI) for G3 (69%) was significantly better compared to DHI noticed for G1 (54%) and G2 (61%) (*p* \< 0.001). For OARs (urethra and rectum), dosimetric results were significantly improved in G3 compare to G1 and G2 (*p* \< 0.001) ([Table 2](#T0002){ref-type="table"}). Assuming αβ 3 Gy for urethra and rectum, EQD2 of the dose delivered by the boost to OARs significantly decreased from G1 to G3 for both urethra (D~10u~: 52, 47, and 46 Gy for G1, G2, and G3, respectively; *p* \< 0.001) and rectum (D~2r~: 28, 27, and 26 Gy for G1, G2, and G3, respectively; *p* \< 0.001) ([Table 2](#T0002){ref-type="table"}).

###### 

Dosimetric data and equivalent doses at 2 Gy for CTV (EQD2 α/β 1.5 Gy) and organs at risk (EQD2 α/β 3 Gy) according to the treatment group

  Data                   3 fractions (G1)   2 fractions (G2)   1 fraction (G3)   *p* value                         
  ---------- ----------- ------------------ ------------------ ----------------- ----------- --------- ----------- ----------
  CTV (cc)   36          (16-60)            33                 (18-54)           32          (11-77)   0.088       
  D~90~      \%          114                (81-138)           111               (95-144)    105       (78-113)    \< 0.001
             EQD2 (Gy)   49                 (26-69)            66                (49-107)    68        (39-78)     \< 0.001
  D~100~     \%          84                 (36-100)           78                (54-98)     78        (43-100)    0.032
             EQD2 (Gy)   28                 (7-39)             34                (18-52)     39        (13-62)     0.012
  V~100~     \%          97                 (83-100)           96                (88-99)     95        (79-100)    0.013
             cc          35                 (30-36)            32                (29-33)     30.4      (25-36)     0.009
  V~150~     \%          45                 (16-81)            36                (25-36)     27        (18-39)     \< 0.001
             cc          16                 (6-29)             12                (8-20)      8.6       (6-12)      \< 0.001
  V~200~     \%          16                 (5-33)             12                (8-19)      9         (6-15)      \< 0.001
             cc          6                  (2-12)             4                 (3-6)       3         (2-5)       \< 0.001
  DHI                    54                 (18-81)            61                (38-72)     69        (43-81)     \< 0.001
  D~0.1u~    \%          150                (113-211)          124               (117-168)   113       (107-120)   \< 0.001
             EQD2 (Gy)   54                 (40-67)            50                (33-66)     48        (33-61)     \< 0.001
  D~1u~      \%          114                (44-153)           101               (11-132)    99        (10-112)    \< 0.001
             EQD2 (Gy)   44                 (32-53)            39                (28-57)     37        (28-50)     \< 0.001
  D~10u~     \%          141                (109-209)          118               (112-146)   112       (105-115)   \< 0.001
             EQD2 (Gy)   52                 (38-65)            47                (31-63)     46        (30-58)     \< 0.001
  D~30u~     \%          130                (105-183)          114               (68-138)    107       (44-111)    \< 0.001
             EQD2 (Gy)   49                 (33-59)            44                (34-59)     42        (32-52)     \< 0.001
  D~0.1r~    \%          102                (91-123)           94                (74-118)    87        (53-99)     \< 0.001
             EQD2 (Gy)   40                 (25-47)            38                (30-50)     36        (29-44)     0.005
  D~1r~      \%          84                 (68-101)           77                (53-91)     70        (31-87)     \< 0.001
             EQD2 (Gy)   32                 (14-41)            31                (22-39)     29        (22-37)     0.008
  D~2r~      \%          76                 (57-93)            68                (46-83)     62        (24-80)     \< 0.001
             EQD2 (Gy)   28                 (11-38)            27                (20-35)     26        (18-33)     0.034

CTV -- clinical target volume (prostate), D~90~ -- dose delivered to 90% of CTV expressed in percentage and in EQD2 with *α*/*β*1.5 Gy, D~100~ -- dose delivered to 100% of CTV expressed in percentage and in equivalence of the dose at 2 Gy per fraction (EQD2) with *α*/*β* 1.5 Gy, V~100~ -- CTV receiving 100% of the prescribed dose expressed in percentage and in cubic centimetres, V~150~ -- CTV receiving 150% of the prescribed dose expressed in percentage and in cubic centimetres, V~200~ -- CTV receiving 200% of the prescribed dose expressed in percentage and in cubic centimetres, DHI -- Dose Homogeneity Index, D~0.1u~ -- dose delivered to 0.1 cc of the urethral volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~1u~ -- dose delivered to 1 cc of the urethral volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~10u~ -- dose delivered to 10% of urethral volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~30u~ -- dose delivered to 30% of urethral volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~01r~ -- dose delivered to 0.1 cc of the rectal volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~1r~ -- dose delivered to 1 cc of the rectal volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy, D~2r~ -- dose delivered to 2 cc of the rectal volume expressed in percentage of the prescribed dose and in EQD2 with *α*/*β* 3 Gy

Acute genito-urinary and gastro-intestinal toxicity analysis {#S20009}
------------------------------------------------------------

The median follow-up was 25 months (ranged 8-46.9). Genito-urinary and GI complication grades for each treatment group were summarized in [Table 3](#T0003){ref-type="table"}. The rates of acute GI and GU toxicities observed at 1 and 6 months after HDR brachytherapy boost were mainly Grade 1 with few Grade 2 (GU: 5% at 1 month; GI: 1% at 6 months). No Grade 3 toxicity was observed in the whole population, while one patient in Group 1 developed Grade 4 GU toxicity consisting in a post-operative septic syndrome treated in intensive-care unit during 14 days. This patient recovered after 1 month without GU complications at 6 months.

###### 

Analysis of genito-urinary (GU) and gastro-intestinal (GI) complications observed at 1 and 6 months after HDRB boost regarding to the complication grade (CTCv3.0) and the different fractionation schemes

  Complications         GU                                     GI            
  --------------------- -------------------------------------- ------ ------ ------
  Grades                                                                     
   0                    61                                     69     74     77
   1                    33                                     31     26     22
   2                    5                                      0      0      1
   3                    0                                      0      0      0
   4                    1                                      0      0      0
  Fract. schemes                                                             
   G1 (18 Gy/3 f/2 d)   22[\*](#TF0001){ref-type="table-fn"}   33     23     45
   G2 (18 Gy/2 f/2 d)   51                                     63     30     50
   G3 (14 Gy/1 f/1 d)   27                                     4      47     5
  *p* value             0.41                                   0.49   0.07   0.34

Percentages of complication among patients who developed GU and/or GI complications

GU -- genito-urinary complications, GI -- gastro-intestinal complications, Fract. schemes -- fractionation schemes

Regarding the acute GU and GI toxicities occurred in the 3 treatment groups, no significant differences were observed at 1 and 6 months after the HDR brachytherapy boost between G1, G2, and G3 treatment groups ([Table 3](#T0003){ref-type="table"}).

Discussion {#S0010}
==========

Dose escalation for prostate cancer radiation treatment represents a key point in order to improve biochemical control. According to the meta-analysis published by Viani *et al*. \[[@CIT0021]\], high-dose radiotherapy was superior to conventional dose radiotherapy in preventing biochemical failure in all risk groups, suggesting that high-dose radiotherapy should be offered to all patients regardless of their risk status. The low α/β ratio indicates that prostate tumours are more sensitive to high radiation doses per fraction than most other malignancies \[[@CIT0016]\]. Therefore, many investigators have directed their efforts to deliver hypofractionated EBRT. In this field, the use of brachytherapy boost in addition to pelvic EBRT up to 46 Gy represents a smart and attractive option \[[@CIT0022], [@CIT0023]\]. Indeed, brachytherapy allows an "intrinsic" dose escalation due to the overdose volumes generated by the interstitial position of the radioactive source within the prostatic tissues, and lead to a biological advantage over external beam radiation boost technique \[[@CIT0024]\]. Brachytherapy boost has not only a potential advantage on clinical outcome, but also allows to make the treatment more acceptable for the patient due to less transportations to the medical insurance for reimbursement, and for the medical staff dealing with a less time consuming procedure. In this field, HDRB appears to give at least equivalent clinical outcomes compared to low-dose rate brachytherapy \[[@CIT0025]\].

A matched-pair analysis comparing prostate cancer EBRT + HDR vs. EBRT alone demonstrated a significant advantage in 5-year biochemical control in favour to the combination modality \[[@CIT0026]\]. Two randomized trials have confirmed the superiority of the combination therapy using either low \[[@CIT0027]\] or high-dose rate \[[@CIT0028]\] iridium sources in terms of biochemical control with at least similar late GU and GI toxicity with a potential advantage for acute rectal complications \[[@CIT0029]\]. However, these studies used as "conventional" EBRT arm a total dose around 70 Gy which is now considered as a low dose regarding biochemical control probability. Nevertheless, even in case of very high-dose delivered to the prostate (86.4 Gy) using a IMRT technique, Deutsch *et al*. \[[@CIT0030]\] showed in a retrospective comparative analysis between EBRT vs. brachytherapy boost that the biochemical control remained significantly better in the brachytherapy group (3 × 7 Gy). Whatever, it remains difficult to compare EBRT with brachytherapy boost techniques, because the dose delivered by brachytherapy will be always higher compare to the same prescribed dose delivered by EBRT (overdose volumes). This fact introduces an initial bias, which complicates the comparison between the two boost techniques. Taking all together, the presented studies bring consistent data to consider brachytherapy boost as an attractive concept.

Currently, there is no standard fractionation scheme, and numerous protocols have been tested with various numbers of fractions (ranged from 1 to 5) and dose per fraction (ranged from 4.75 to 15 Gy) \[[@CIT0013]\]. It appears more comfortable for both patient and medical staff to reduce as far as possible the number of brachytherapy fractions respecting a similar biological effect, and clinical outcome in terms of toxicity and efficacy. In this filed, we started our brachytherapy boost program using 3 fractions in 2 days (3 × 6 Gy), while one fraction of 14 Gy became our standard protocol allowing to implant the needles, treat the patient and remove all the materials in the same day (one day procedure). According to acute GI and GU toxicities, Hoskin *et al*. \[[@CIT0029]\] reported in a phase III randomised trial that HDRB boost technique could significantly reduce GI toxicity with equivalent GU complication rates compared to those observed with EBRT. Regarding acute GI and GU toxicities, we reported mainly grade 1 complications and especially no significant differences between the 3 fractionations schemes. Furthermore, the dose distribution improved according to the learning curve, although the dose constraints for OARs were more restrictive. Our results in terms of EQD2 for urethra and rectum (Boost EQD2 + EBRT 46 Gy) respect the recently published GEC-ESTRO recommendations \[[@CIT0015]\], which propose for urethra D~0.1cc~ and D~10~ ≤ 120 Gy EQD2 with D~30~ ≤ 105 Gy EQD2, and for rectum D~2cc~ ≤ 75 Gy EQD2.

Currently, the right fractionation remains under debate, but following strict implantation rules \[[@CIT0031]\], there is a strong rational to propose a prostate cancer HDRB boost using a single fraction, providing similar results in terms of acute toxicity, and more comfortable procedure for patient and less time consuming for medical staff. However, longer follow-up is needed to confirm that single fraction of HDRB used as boost will give consistent results in terms of clinical outcome.

Conclusions {#S0011}
===========

The right fractionation remains under discussion, but prostate cancer HDRB boost using a single fraction (providing similar results in terms of acute toxicity) is more comfortable for the patient, less time consuming for the medical staff.
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